Vest Financial LLC Has $1.80 Million Position in Thermo Fisher Scientific Inc. $TMO

Vest Financial LLC grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 39.3% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 4,440 shares of the medical research company’s stock after purchasing an additional 1,252 shares during the quarter. Vest Financial LLC’s holdings in Thermo Fisher Scientific were worth $1,800,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Thermo Fisher Scientific by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company’s stock valued at $16,659,627,000 after buying an additional 230,382 shares in the last quarter. Amundi increased its position in Thermo Fisher Scientific by 5.9% during the 1st quarter. Amundi now owns 3,029,044 shares of the medical research company’s stock worth $1,426,316,000 after purchasing an additional 168,197 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Thermo Fisher Scientific by 4.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company’s stock worth $1,455,774,000 after purchasing an additional 115,463 shares in the last quarter. Pictet Asset Management Holding SA increased its position in Thermo Fisher Scientific by 7.2% during the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company’s stock worth $1,432,816,000 after purchasing an additional 193,378 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Thermo Fisher Scientific by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock worth $1,368,859,000 after purchasing an additional 329,974 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Evercore ISI upped their price objective on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Hsbc Global Res cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Tuesday. HSBC restated a “hold” rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, JPMorgan Chase & Co. upped their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. Fifteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $589.10.

Insider Activity

In related news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Trading Up 0.1%

NYSE:TMO opened at $525.08 on Wednesday. The firm’s fifty day moving average is $491.00 and its 200-day moving average is $448.20. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The firm has a market cap of $198.28 billion, a P/E ratio of 30.37, a P/E/G ratio of 2.85 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period in the prior year, the firm posted $5.37 EPS. The company’s quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.